These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 21257294)
1. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Leucht C; Heres S; Kane JM; Kissling W; Davis JM; Leucht S Schizophr Res; 2011 Apr; 127(1-3):83-92. PubMed ID: 21257294 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008 [TBL] [Abstract][Full Text] [Related]
3. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Adams CE; Fenton MK; Quraishi S; David AS Br J Psychiatry; 2001 Oct; 179():290-9. PubMed ID: 11581108 [TBL] [Abstract][Full Text] [Related]
4. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
5. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Leucht S; Tardy M; Komossa K; Heres S; Kissling W; Salanti G; Davis JM Lancet; 2012 Jun; 379(9831):2063-71. PubMed ID: 22560607 [TBL] [Abstract][Full Text] [Related]
6. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482 [TBL] [Abstract][Full Text] [Related]
7. [The significance of depot medication in the long-term-treatment of schizophrenia]. Kühn KU; Wiedemann K; Hellweg R; Möller HJ Fortschr Neurol Psychiatr; 2014 Oct; 82(10):557-65. PubMed ID: 25299626 [TBL] [Abstract][Full Text] [Related]
8. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review. Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334 [TBL] [Abstract][Full Text] [Related]
9. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia. Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950 [TBL] [Abstract][Full Text] [Related]
10. Clozapine versus typical neuroleptic medication for schizophrenia. Wahlbeck K; Cheine M; Essali MA Cochrane Database Syst Rev; 2000; (2):CD000059. PubMed ID: 10796289 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Fusar-Poli P; Kempton MJ; Rosenheck RA Int Clin Psychopharmacol; 2013 Mar; 28(2):57-66. PubMed ID: 23165366 [TBL] [Abstract][Full Text] [Related]
12. Long-term depot antipsychotics. A risk-benefit assessment. Barnes TR; Curson DA Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075 [TBL] [Abstract][Full Text] [Related]
13. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study. Brnabic AJ; Kelin K; Ascher-Svanum H; Montgomery W; Kadziola Z; Karagianis J Int J Clin Pract; 2011 Sep; 65(9):945-53. PubMed ID: 21849009 [TBL] [Abstract][Full Text] [Related]
14. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics. De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744 [TBL] [Abstract][Full Text] [Related]
15. The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Kahn RS; Giannopoulou A Expert Rev Neurother; 2015; 15(9):969-81. PubMed ID: 26289486 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes. Muirhead D; Harvey C; Ingram G Aust N Z J Psychiatry; 2006; 40(6-7):596-605. PubMed ID: 16756586 [TBL] [Abstract][Full Text] [Related]
17. Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Möller HJ Eur Psychiatry; 2005 Aug; 20(5-6):379-85. PubMed ID: 15994065 [TBL] [Abstract][Full Text] [Related]
18. Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome. Olagunju AT; Clark SR; Baune BT Aust N Z J Psychiatry; 2019 Jun; 53(6):509-527. PubMed ID: 30957510 [TBL] [Abstract][Full Text] [Related]
19. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Walburn J; Gray R; Gournay K; Quraishi S; David AS Br J Psychiatry; 2001 Oct; 179():300-7. PubMed ID: 11581109 [TBL] [Abstract][Full Text] [Related]
20. The effect of financial incentives on patients' motivation for treatment: results of "Money for Medication," a randomised controlled trial. Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AFT; Mulder CL BMC Psychiatry; 2018 May; 18(1):144. PubMed ID: 29793451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]